Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Annette Hall

Nurse Practitioner Springfield, OH Nurse Practitioner

NPI 1235763012 CMS profile 11178154

30 W McCreight Ave Ste 100, Springfield, OH 45504

Open in the dashboard

General payments

$3,343

149 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Annette Hall of Springfield, OH is reported in the CMS Open Payments database as having received $3,343 across 149 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,559 77
2024 General $1,142 42
2023 General $360 20
2022 General $281 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Annette Hall
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Annette Hall were reported at $1,559. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Annette Hall Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $281 $152 $48–$470 $149
2023 $360 $166 $54–$529 $160
2024 $1,142 $173 $55–$556 $164
2025 $1,559 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $1,016 35 payments
  2. GlaxoSmithKline, LLC. $534 39 payments
  3. Jazz Pharmaceuticals Inc. $461 10 payments
  4. Genzyme Corporation $363 21 payments
  5. Sanofi-Aventis U.S. LLC $195 2 payments
  6. Regeneron Healthcare Solutions, Inc. $137 7 payments
  7. Insmed, Inc. $103 6 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $84 4 payments
  9. Mylan Specialty L.P. $79 4 payments
  10. Grifols USA, LLC $66 4 payments
  11. Other $306 17 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,932 144 payments
  2. Education $411 5 payments
Products named General payments · program years 2022–2025
  1. DUPIXENT $558 23 payments
  2. BREZTRI $547 16 payments
  3. XYWAV $461 10 payments
  4. FASENRA $306 12 payments
  5. AIRSUPRA $251 6 payments
  6. TRELEGY ELLIPTA $228 22 payments
  7. NUCALA $187 15 payments
  8. YUPELRI $130 7 payments
  9. AREXVY $118 2 payments
  10. Arikayce $86 5 payments
  11. Other $785 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,396

Median for Nurse Practitioner: 389

Drug cost

$448,701

Median for Nurse Practitioner: $21,885

Branded share of claims

80.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 189 $160,113
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 96 $70,775
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 85 $47,187
Spiriva Respimat Tiotropium Bromide Brand 57 $39,851
Breo Ellipta Fluticasone/Vilanterol Brand 73 $34,883
Bevespi Aerosphere Glycopyrrolate/Formoterol Fum Brand 39 $19,111
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 29 $17,699
Symbicort Budesonide/Formoterol Fumarate Brand 54 $16,683
Incruse Ellipta Umeclidinium Bromide Brand 28 $10,874
Albuterol Sulfate Hfa Albuterol Sulfate Brand 381 $9,064

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$13,801

Medicare's payments for the services billed

Medicare patients

118

Average age 73

Services billed

194

66 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 64%
Arthritis 58%
Depression 44%
Ischemic heart disease 43%
Diabetes 30%
Atrial fibrillation 27%
Chronic kidney disease 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • SANOFI-AVENTIS U.S. LLC $195
  • GENZYME CORPORATION $146
  • Regeneron Healthcare Solutions, Inc. $67
$408 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $198
$198 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $135
$135 — —
AREXVY
  • GlaxoSmithKline, LLC. $118
$118 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $70
$70 189 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record